STERIS plc (STE)

STERIS: A Healthcare-Infrastructure Compounder That Just Simplified Its Portfolio

If you are looking for a story stock that could 10x in a year, STERIS is not it. But if you want a company running a business that hospitals and pharmaceutical manufacturers genuinely cannot operate without, regardless of the economic cycle, STERIS deserves a closer look.

STERIS plc (NYSE: STE) is a medical device company focused on sterilization and infection prevention. In plain terms, STERIS sells sterilizers, washers, surgical tables and lights, consumables, and contract sterilization services to hospitals, surgery centers, and pharmaceutical/biotech manufacturers. It is not a flashy business, but it is genuinely foundational infrastructure for modern healthcare delivery — every surgical instrument must be sterilized before reuse, and that is STERIS's core job.

A Portfolio-Simplification Story

The most important thing to understand about STERIS right now is that the company just simplified its portfolio. In May 2024, STERIS sold its Dental segment to an affiliate of Peak Rock Capital for USD787.5 million (plus up to USD12.5 million in earnout). Dental was a lower-growth business that no longer fit the company's core thesis. Proceeds went primarily toward debt repayment.

Following the Dental sale, STERIS now operates three continuing-operations segments:

• Healthcare (largest segment) — capital equipment (sterilizers, washers, surgical tables/lights), consumables, and maintenance services sold to hospitals and surgery centers. FY2026 growth: +9% as reported, with service revenue up +12%, reflecting a shift toward higher-margin recurring revenue.
• Applied Sterilization Technologies (AST) — outsourced contract sterilization (gamma, e-beam, ethylene oxide/EtO) for medical device and pharma customers. FY2026 growth: +10%. This segment crossed USD1 billion in revenue and USD500 million in operating profit for the first time in FY2026 — a milestone flagged prominently on the earnings call.
• Life Sciences — sterilization and decontamination equipment and services for pharma/biotech manufacturers. FY2026 growth: +9%.

Growth is broad-based across all three segments (roughly 7-8% organic each) — this is not a single-product story but a diversified healthcare-infrastructure business.

Shariah Compliance Status

✅ SHARIAH COMPLIANT — Per the Zoya US stock reference, STERIS plc is confirmed as a Shariah-compliant stock. This makes it a viable candidate for investors seeking Shariah-compliant exposure to the US healthcare sector.

Tax Domicile Structure

One notable fact: STERIS is legally domiciled in Dublin, Ireland, while its actual operational headquarters sits in Mentor, Ohio. This structure traces back to a corporate tax inversion dating to 2015 — the full story is discussed in the gold section below.

This section is being refreshed with the latest figures. Please check back soon.

This section is being refreshed with the latest figures. Please check back soon.